Skip to content
Open access

Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.

Sep 2026 · Brachytherapy · 0 citations · 47 references
Medicine

TL;DR

PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.

Abstract

Objective

To assess late toxicities, cosmesis, and oncological outcomes in patients treated with Partial Breast Irradiation (PBI) using interstitial multi-catheter high dose-rate brachytherapy.

Methods

From 2003 to 2023, 292 patients were enrolled in a prospective observational study (follow-up up to 20 years). INCLUSION CRITERIA age ≥40 years; ECOG 0-2; ductal carcinoma in situ; invasive non lobular carcinoma; tumor size ≤2.5 cm; negative axillary lymph nodes; surgical margins ≥2 mm. PBI dose was 32 Gy in 8 fractions over 4 days.

Results

Invasive carcinoma accounted for 92.1% of cases. Late toxicities (mainly telangiectasia, fibrosis, liponecrosis) occurred in 100/286 patients evaluated (35%). Cosmetic outcomes were rated as excellent/good in 96% of cases. Ipsilateral breast tumor recurrence occurred in 10 patients (3.4%) with a 5-year cumulative incidence of 1.8% and 3.8% at 10 and 15 years. Breast cancer-free specific survival was 98.4% after 5 years, 95.7% after 10 years, and 94% after 15 years. Overall survival was 93% after 5 years, 69% after 10 years, and 53.4% after 15 years.

Conclusions

PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.

Read PDF

Similar papers

Open access Oct 2026

Permanent low-dose-rate seed implantation as single-session partial breast irradiation: Long-term outcomes using a modified institutional protocol.

PURPOSE To report long-term oncologic, cosmetic, and toxicity outcomes of permanent breast seed implantation (PBSI) using palladium-103 as accelerated partial breast irradiation (APBI) for early-stage breast cancer. METHODS AND MATERIALS This prospective, single-institution study enrolled 27 patients in 2013-2015. Ou...

U. Amit, T. Meyer, M. Roumeliotis et al. · 0 citations
Review Oct 2026

Safety and early outcomes of external beam radiation therapy with low dose brachytherapy boost in patients with prostate cancer: A single institution experience.

Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.

Z. El Kouzi, M. Rooney, Adam B. Samman et al. · 0 citations
Open access Sep 2026

Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study

Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.

E. Ogo, T. Arimura, T. Ogino et al. · 0 citations
Open access Sep 2026

Image-guided high-dose-rate brachytherapy after short-course external beam radiotherapy for elderly/frail rectal cancer patients.

HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control and the incidence of late grade 3 rectal bleeding requires careful patient selection.

Alexander Kristen, N. Tselis, M. Diefenhardt et al. · 0 citations
Sep 2026

High-dose-rate brachytherapy boost with external beam radiotherapy for localized prostate cancer: Long-term outcomes and toxicity in 607 predominantly high-risk patients.

OBJECTIVE To report long-term outcomes and late toxicity after external beam radiotherapy (EBRT) with single-fraction high-dose-rate brachytherapy boost (HDR-BTB) for localized prostate cancer, examining HDR-BT sequencing and risk stratification. METHODS AND MATERIALS We retrospectively analyzed 607 (2012-2023) men t...

M. Choudhury, F. Adeoye, S. Nageshwaran et al. · 0 citations
Open access Oct 2026

Long-term results of stereotactic body radiotherapy boost in patients with cervical cancer considered unsuitable for intracavitary brachytherapy.

PURPOSE Although stereotactic body radiotherapy (SBRT) boost represents a promising treatment option for patients with locally advanced cervical cancer who were considered unsuitable for brachytherapy, its long-term efficacy and safety remain unclear. This study assessed long-term oncologic outcomes and late toxicities...

K. Ito, Y. Nakajima, H. Ogawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.